

CUTANEOUS LUPUS ERYTHEMATOSUS

In order to facilitate future clinical trials, Albrecht et al¹ developed and validated an outcome measure named the CLASI-Cutaneous Lupus Erythematosus Disease Area and Severity Index, for lupus erythematosus. The CLASI addresses disease affecting any part of the skin but also specifically the scalp and incorporates separate scores for scarring and activity.

| Select the score in each anatomical location that | describes the most severely affected cutaneous lupus-associated lesion |
|---|--|
| activity | damage |

| Anatomical Locat | ion Erythema | Scale/ Hypertrophy | Dyspigmentation | Scarring/ Atrophy/ Panniculitis | Anatomical Location |
|-----------------------|--|---|-------------------------------|--|---------------------------|
| | 0-absent 1-pink; faint erythema 2- red; 3-dark red; purple/violaceous/ crusted/ hemorrhagic | 1-scale 2-verrucous/ hypertrophic | 0-absent, 1-dyspigmentaton | 0 absent 1 scarring 2 severely atrophic scarring or panniculitis | |
| Scalp | | | | See below | Scalp |
| Ears | | | | | Ears |
| Nose (incl. malar are | a) | | | | Nose (incl. malar area) |
| Rest of the face | | | | | Rest of the face |
| V-area neck (frontal) | | | | | V-area neck (frontal) |
| Post. Neck &/or sho | ulders | | | | Post. Neck &/or shoulders |
| Chest | | | | | Chest |
| Abdomen | | | | | Abdomen |
| Back, buttocks | | | | | Back, buttocks |
| Arms | | | | | Arms |
| Hands | | | | | Hands |
| Legs | | | | | Legs |
| Feet | | | | | Feet |

| Mucous membrane | Dyspigmentation | | |
|---|--|--|--|
| Mucous membrane lesions (examine if patient confirms involvement | Report duration of dyspigmentation after active lesions have resolved (verbal report by patient tick appropriate box) | | |
| 0-absent; | Dyspigmentation usually lasts less than 12 months (dyspigmentation score above remains) | | |
| 1-lesion or ulceration | Dyspigmentation usually lasts at least 12 months (dyspigmentation score is doubled) | | |
| Alopecia | | | |
| Recent Hair loss (within the last 30 days/as reported by patient) | NB: if scarring and non-scarring aspects seem | | |
| 1-Yes O-No | to coexist in one lesion, please score both | | |
| Divide the scalp into four quadrants as shown. The dividing line betw is the line connecting the highest points of the ear lobe. A quadrant i | ween right and left is the midline. The dividing line between frontal and occipital is considered affected if there is a lesion within the quadrant. | | |
| Alopecia (clinically not obviously scarred) | Scarring of the scalp (judged clinically) | | |
| 0-absent 1-diffuse; non-inflammatory 2-focal or patchy in one quadrant; 3-focal or patchy in more than one quadrant | 0- absent 3- in one quadrant 4- two quadrants 5- three quadrants 6- affects the whole skull | | |
| Total Activity Score | Total Damage Score | | |
| Total Activity Score (For the activity score please add up the scores of the left side i.e. for Erythema, Scale/Hypertrophy, Mucous membrane involvement and Alopecia) | Total Damage Score (For the damage score, please add up the scores of the right side, i.e. for Dyspigmentation, Scarring/Atrophy/Panniculitis and Scarring of the Scalp) | | |

¹ Albrecht J et al, 'The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. 'J Invest Dermatol. 2005 Nov;125(5):889-94.